Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Core Insights - Hoth Therapeutics, Inc. announced positive interim results from the CLEER-001 clinical trial, demonstrating significant improvements in disease severity and patient-reported symptoms for cancer patients receiving EGFR inhibitor therapy [1][2][6]. Group 1: Primary Endpoint Results - The primary endpoint, assessed using the ARIGA scale, showed a ~50% reduction in disease severity, with mean ARIGA scores improving from 1.67 at baseline to 0.83 by Week 6 [3][4]. - All evaluable patients achieved ARIGA 1 by Week 6, indicating they fell within the low-severity disease range, with improvements noted as early as Week 3 [4]. Group 2: Additional Endpoints - The trial also reported a ~34% improvement in oncology toxicity (CTCAE), with scores decreasing from 2.0 at baseline to 1.33 at Week 6 [7]. - Patient-reported pruritus scores improved by ~37%, from a mean of 4.22 at baseline to 2.67 at Week 6, indicating a significant reduction in symptom severity [7]. Group 3: Treatment Context and Implications - EGFR inhibitors are critical in treating various cancers, but they often lead to treatment-related toxicity that can hinder patient outcomes [6]. - The results from CLEER-001 suggest that HT-001 could play a vital role in supportive care, helping patients maintain their cancer treatment regimens [6][8]. Group 4: Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at improving the quality of life for cancer patients [9].